Skip to main content
Premium Trial:

Request an Annual Quote

Fluent BioSciences, NanoCellect Partner on Single-Cell RNA-seq Workflows

NEW YORK – Fluent BioSciences and NanoCellect Biomedical said today that they are collaborating to improve the resolution and efficiency of single-cell RNA sequencing (scRNA-seq) analysis of rare cell populations.

Single-cell researchers require scalable, flexible, and accessible workflows, and the combination of cell sorting on the NanoCellect platform followed by scRNA-seq on Fluent's instrument-free platform using pre-templated instant partitions (PIPseq) can be an efficient solution for a wide range of single-cell applications across oncology, immunology, and neuroscience, the companies said.

"Reliable and reproducible sample preparation is critically important to the scRNA-seq workflow," Jose Morachis, president and cofounder at NanoCellect, said in a statement. "NanoCellect's Wolf and Wolf G2 Cell Sorters can function as a valuable step in the scRNA-seq workflow by isolating only cells of interest while removing dead cells and debris, thus improving scRNA-seq resolution of rare cell populations of interest and overall sequencing data quality."

Earlier this year, Watertown, Massachusetts-based Fluent Biosciences won a $1.7 million Small Business Innovation Research grant from the National Institutes of Health to fund reproducibility testing and commercialization of its PIPseq technology for single-cell analysis.

San Diego-based NanoCellect last year closed two financing rounds totaling $35 million to accelerate its commercial growth and further development of its Wolf cell sorting systems.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.